Cargando…

Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors

Parkinson’s disease (PD) is a progressive neurodegenerative disorder caused mainly by lack of dopamine in the brain. Dopamine is a neurotransmitter involved in movement, motivation, memory, and other functions; its level is decreased in PD brain as a result of dopaminergic cell death. Dopamine loss...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emamzadeh, Fatemeh N., Surguchov, Andrei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125353/ https://www.ncbi.nlm.nih.gov/pubmed/30214392 http://dx.doi.org/10.3389/fnins.2018.00612

Ejemplares similares

Cell Responses to Extracellular α-Synuclein
por: Surguchev, Alexei A., et al.
Publicado: (2019)

Amyloidosis and Longevity: A Lesson from Plants
por: Surguchov, Andrei, et al.
Publicado: (2019)

Controversial Properties of Amyloidogenic Proteins and Peptides: New Data in the COVID Era
por: Surguchov, Andrei, et al.
Publicado: (2023)

Invertebrate Models Untangle the Mechanism of Neurodegeneration in Parkinson’s Disease
por: Surguchov, Andrei
Publicado: (2021)

Commentary: α-Synuclein Interacts with Lipoproteins in Plasma
por: Surguchov, Andrei
Publicado: (2017)

Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
por: Emamzadeh, Fatemeh Nouri
Publicado: (2017)

Parkinson’s Disease: Assay of Phosphorylated α-Synuclein in Skin Biopsy for Early Diagnosis and Association with Melanoma
por: Surguchov, Andrei
Publicado: (2016)

Synucleins and Gene Expression: Ramblers in a Crowd or Cops Regulating Traffic?
por: Surguchev, Alexei A., et al.
Publicado: (2017)

Bone-Derived Factors as Potential Biomarkers for Parkinson’s Disease
por: Lin, Yuwan, et al.
Publicado: (2021)

Pore-Forming Proteins as Mediators of Novel Epigenetic Mechanism of Epilepsy
por: Surguchov, Andrei, et al.
Publicado: (2017)

Recent Advances in Biomarkers for Parkinson’s Disease
por: He, Runcheng, et al.
Publicado: (2018)

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes
por: Lin, Chin-Hsien, et al.
Publicado: (2018)

Evaluation of RNA Blood Biomarkers in the Parkinson’s Disease Biomarkers Program
por: Santiago, Jose A., et al.
Publicado: (2018)

Biomarkers and the Role of α-Synuclein in Parkinson’s Disease
por: Du, Tingting, et al.
Publicado: (2021)

Analysis of Protein Conformational Strains—A Key for New Diagnostic Methods of Human Diseases
por: Surguchov, Andrei
Publicado: (2020)

Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease
por: Avenali, Micol, et al.
Publicado: (2020)

Integrated Analysis and Identification of Novel Biomarkers in Parkinson’s Disease
por: Chi, Jieshan, et al.
Publicado: (2018)

Circulating miRNAs as Diagnostic Biomarkers for Parkinson’s Disease
por: Roser, Anna Elisa, et al.
Publicado: (2018)

Editorial: Biomarkers and Pathogenesis of Alpha-Synuclein in Parkinson's Disease
por: Li, Puyu, et al.
Publicado: (2021)

Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases
por: Chin-Chan, Miguel, et al.
Publicado: (2015)

Ca(2+) Dyshomeostasis Links Risk Factors to Neurodegeneration in Parkinson’s Disease
por: Xu, Jianjun, et al.
Publicado: (2022)

Synucleins: New Data on Misfolding, Aggregation and Role in Diseases
por: Surguchov, Andrei, et al.
Publicado: (2022)

Quantitative Electroencephalography as a Biomarker for Cognitive Dysfunction in Parkinson’s Disease
por: Novak, Kevin, et al.
Publicado: (2022)

Neurofilament light as a biomarker for motor decline in Parkinson’s disease
por: Liu, Yumei, et al.
Publicado: (2022)

Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson’s Disease
por: Franco, Rafael, et al.
Publicado: (2020)

Alpha-Synuclein as a Biomarker of Parkinson’s Disease: Good, but Not Good Enough
por: Ganguly, Upasana, et al.
Publicado: (2021)

Proteomics Challenges for the Assessment of Synuclein Proteoforms as Clinical Biomarkers in Parkinson’s Disease
por: Pons, Marie-Laure, et al.
Publicado: (2022)

Monogenetic Forms of Parkinson’s Disease – Bridging the Gap Between Genetics and Biomarkers
por: Tönges, Lars, et al.
Publicado: (2022)

The Potential Circular RNAs Biomarker Panel and Regulatory Networks of Parkinson’s Disease
por: Xiao, Yousheng, et al.
Publicado: (2022)

Emerging Treatment Approaches for Parkinson’s Disease
por: Stoker, Thomas B., et al.
Publicado: (2018)

Surgical Treatment of Dyskinesia in Parkinson’s Disease
por: Munhoz, Renato P., et al.
Publicado: (2014)

α-Synuclein and Mechanisms of Epigenetic Regulation
por: Surguchov, Andrei
Publicado: (2023)

Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson’s Disease
por: Wu, Zubo, et al.
Publicado: (2021)

Serum glial cell line-derived neurotrophic factor (GDNF) a potential biomarker of executive function in Parkinson’s disease
por: Tong, Shu-Yan, et al.
Publicado: (2023)

The Correlation between Osteoporosis Occurrences in Both Schizophrenia and Parkinson’s Disease
por: Radaei, Fatemeh, et al.
Publicado: (2014)

MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease
por: Arshad, Ahmad R., et al.
Publicado: (2017)

Serum miR-214 Serves as a Biomarker for Prodromal Parkinson’s Disease
por: Li, Lanting, et al.
Publicado: (2021)

Decreased soluble Nogo-B in serum as a promising biomarker for Parkinson's disease
por: Liang, Hongming, et al.
Publicado: (2022)

Novel diagnostic biomarkers related to immune infiltration in Parkinson’s disease by bioinformatics analysis
por: Zhang, Pengfei, et al.
Publicado: (2023)

Towards biomarker-based optimization of deep brain stimulation in Parkinson’s disease patients
por: Peeters, Jana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ed6nslrho777fna7r905uv8jio